CN109082426A - 利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 - Google Patents
利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 Download PDFInfo
- Publication number
- CN109082426A CN109082426A CN201811032925.9A CN201811032925A CN109082426A CN 109082426 A CN109082426 A CN 109082426A CN 201811032925 A CN201811032925 A CN 201811032925A CN 109082426 A CN109082426 A CN 109082426A
- Authority
- CN
- China
- Prior art keywords
- cip2a
- zebra fish
- mutation
- grna
- microlitres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 53
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 36
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 title claims abstract description 15
- 238000010276 construction Methods 0.000 title claims description 3
- 230000035772 mutation Effects 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 238000013461 design Methods 0.000 claims abstract description 10
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 6
- 238000000520 microinjection Methods 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 23
- 108091033409 CRISPR Proteins 0.000 claims description 22
- 108020005004 Guide RNA Proteins 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001962 electrophoresis Methods 0.000 claims description 11
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000012790 confirmation Methods 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000002205 phenol-chloroform extraction Methods 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000004925 denaturation Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 101100220708 Mus musculus Cip2a gene Proteins 0.000 claims description 2
- 238000010222 PCR analysis Methods 0.000 claims description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 210000002257 embryonic structure Anatomy 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000014616 translation Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 238000010448 genetic screening Methods 0.000 abstract 2
- 238000012795 verification Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 5
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 101000766826 Homo sapiens Protein CIP2A Proteins 0.000 description 2
- 102100028634 Protein CIP2A Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 101710098065 Protein CIP2A Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于生物技术领域,具体涉及一种利用CRISPR‑Cas9构建斑马鱼cip2a基因突变体以及使用该方法构建的斑马鱼cip2a基因突变体。其中包括了cip2a基因座上Cas9‑gRNA靶位点的设计,Cas9mRNA和cip2a‑gRNA的合成,以及体内显微注射和后续遗传筛选。该靶位点的序列位于cip2a基因第二个外显子上;同时设计一对包含靶位点的引物,通过PCR进行靶位点突变的验证。该验证方式同样适用于后续遗传筛选。本发明所述的利用CRISPR‑Cas9技术构建的cip2a斑马鱼突变体表现出高突变率,且突变造成了Cip2a蛋白翻译的提前终止。此外,本发明所述的cip2a基因突变斑马鱼仅通过连续的两代筛选就得到了。本发明获得了2种突变类型的cip2a突变体斑马鱼系。
Description
技术领域
本发明涉及分子生物学领域,特别涉及一种利用CRISPR-Cas9构建斑马鱼cip2a基因突变体的方法以及使用该方法构建的斑马鱼cip2a基因突变体。
背景技术
蛋白质磷酸酶2A(Protein phosphatase 2A PP2A)是一种重要的肿瘤抑制因子,而抑制其表达可促进人类癌细胞的各种恶性特征。在癌症中,一组PP2A的阻遏蛋白抑制了PP2A的表达。其中,cip2a(Cancerous Inhibitor of Protein Phosphatase 2A)是一种重要的PP2A内源癌性抑制剂,它由基因KIAA1524编码。cip2a能抑制细胞内蛋白磷酸酶PP2A对c-MYC蛋白的去磷酸化作用,从而稳定c-MYC蛋白表达水平,促进细胞转化和体内肿瘤的生长。还能通过抑制PP2A来激活几种关键的癌症驱动因子(Akt,MYC,E2F1等)的活性,并促进大多数癌症类型的恶性表型。此外,cip2a在许多肿瘤中都呈现出高水平的表达,而在多种良性组织细胞中表达量都很低。值得注意的是,在十几种不同癌症类型患者中,cip2a蛋白的高表达都预测了较低的生存率。因此,cip2a在癌症治疗的预后和功能相关性等方面有着重要的意义。
斑马鱼是一种用于研究脊椎动物胚胎学和发育遗传学的模式生物,基于其快速迭代的优势,可以很好地用于癌症肿瘤学的研究。在斑马鱼中cip2a基因被称作蛋白磷酸酶2A细胞增殖调节抑制剂(cell proliferation regulating inhibitor of proteinphosphatase 2A,cip2a)。目前在斑马鱼中对于cip2a基因功能的研究仍是缺失的,本专利通过CRSPR-Cas9建立了斑马鱼cip2a的突变体,为进一步研究cip2a的功能提供了材料基础。
CRISPR/Cas9是细菌和古细菌在长期演化过程中形成的一种适应性免疫防御,可用来对抗入侵的病毒及外源DNA。CRISPR是指规律成簇的间隔短回文重复序列(Clusteredregularly interspaced short palindromic repeat,CRISPR),最早是由日本科学家Ishino在大肠杆菌中发现。Cas则指的是CRISPR相关蛋白,一般定位于CRISPR位点附近,是一个有多种亚型多肽的蛋白家族,而Cas9是应用最为广泛的一个亚型。2013年1月,Woong YHwang等首次将该技术应用于斑马鱼基因编辑中。通过外源导入靶向基因组的gRNA和Cas9mRNA,gRNA即可引导Cas9蛋白切割基因组靶点附近的DNA双链,进而引发细胞的错配修复,从而造成基因突变。
发明内容
本发明目的在于构建了斑马鱼cip2a基因的突变体。
为实现上述构建斑马鱼cip2a基因突变体的目的,本发明提供的技术方案是:
1.根据cip2a基因序列设计Cas9靶位点;
2.确认靶位点在斑马鱼基因组中的特异性;
3.显微共注射cip2a-gRNA和Cas9 mRNA到斑马鱼胚胎,并验证突变效率;
4.饲养F0胚胎至性成熟,和野生型外交,检测F1胚胎突变类型;
5.饲养F1胚胎至1月龄,鉴定突变类型,相同突变类型集中饲养;
6.相同突变类型F1成鱼自交,得到F2胚胎,生长到1月龄鉴定纯合子;
7.得到2种突变类型的纯合F2成鱼,自交获得稳定遗传的突变体后代。
借助本发明,至少可以达到以下有益效果:
1.获得cip2a基因纯合突变体;
2.为研究cip2a基因功能提供材料;
3.该基因突变体可用于癌症的治疗及预后的功能性研究。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例并配合符图详细说明如下。
附图说明
图1为cip2a基因突变体构建示意图。图示cip2a突变体构建示意图,显示了cip2a基因座21个外显子,设计Cas9靶位点位于第2个外显子上,绿色竖线指示翻译起始密码子ATG,蓝色竖线指示终止密码子TGA;中间显示了靶位点突变类型,分别为缺失几个碱基和缺失碱基;下图显示预测的氨基酸长度,野生型氨基酸为896个,突变体的Cip2a蛋白翻译都提前终止,缺失7个碱基和4个碱基突变类型对应氨基酸分别为426个和258个。
图2为cip2a-gRNA的电泳条带结果图。图示cip2a-gRNA的电泳条带结果,条带单一,且符合预期大小,约123bp。
图3为斑马鱼cip2a基因第二个外显子序列。本发明构建突变体所设计的Cas9靶位点位于此外显子上。
图4为cip2a基因Cas9靶序列。图示本本发明构建突变体所设计的Cas9靶位点序列。
图5为cip2a突变位点PCR鉴定序列。图示本发明构建突变体所设计的PCR鉴定序列,序列长度为123bp。
图6为cip2a基因鉴定引物P1序列。图示本发明构建突变体所设计的PCR鉴定上游引物。
图7为cip2a基因鉴定引物P2序列。图示本发明构建突变体所设计的PCR鉴定下游引物。
图8为cip2a基因gRNA合成引物P3序列。图示本发明构建突变体所设计gRNA合成上游引物。
图9为cip2a基因序列。图示本发明构建突变体的基因序列,其中蓝色序列为蛋白编码序列,位于外显子上;灰色序列为内含子序列;褐色序列为外显子非翻译区。
具体实施方式
下面结合附图和实施例,对本发明具体实施方式作进一步详细的描述。以下实施例用于说明本发明,但不用于限制本发明的范围。
实施例1
本发明一较佳实施例提供一种利用CRISPR-Cas9构建斑马鱼cip2a基因突变体的方法,具体包括以下步骤:
1.首先,设计cip2a基因Cas9靶位点,方法如下:
A.从Ensemble网站上获取cip2a的蛋白编码序列(CDS),如附图9所示;
B.运用http://zifit.partners.org/ZiFiT/CSquare9Nuclease.aspx网站设计靶位点,打开网站,输入cip2a蛋白编码序列;
C.设定靶位点长度为20个碱基,靶点3’端的3个碱基构成PAM区,序列为NGG(N为任意碱基),输出靶位点序列;
D.cip2a基因的Cas9靶位点序列为:5’-CCAGTCACGCACTGACCGGGACC-3’,为反义链靶点,位于第2个外显子,如附图3-4所示。
2.进一步的,所述的确认cip2a-Cas9靶位点的方法如下:
A.在Ensemble网站上比对靶位点序列,比对结果显示靶点是cip2a基因的单一位点;
B.在靶位点上下游设计引物,5’端引物为,5’-GAGTGCTGTTCTCGGGTCAG-3’,如附图6所示,3’端引物为,5’-ATACCAAATTGTGCCAGCAG-3’,如附图7所示,产物大小为123个碱基对,从野生型斑马鱼基因组中PCR扩增这段序列,其中应包含靶点序列,如附图5所示,PCR程序为:95℃预变性5min,95℃变性30sec,60℃退火30sec,72℃延伸10sec,40循环。PCR扩增产物2%琼脂糖凝胶电泳,大小符合预期;
C.将PCR产物进行测序,测序结果和预测靶点序列一致。
3.进一步的,制备cip2a-gRNA,具体步骤如下:
A.根据靶位点设计gRNA体外转录模板的上游引物,命名为P3,序列为,5’-GATCACTAATACGACTCACTATAGGTCCCGGTCAGTGCGTGACGTTTTAGAGCTAGAAAT-3’,如附图8所示,下游引物使用pT7-gRNA质粒上的通用引物,命名为P4。
B.用P3和P4引物对,以体外转录载体pT7-gRNA质粒为模板,使用高保真酶PCR扩增得到cip2a-gRNA体外转录模板,PCR体系为:模板1微升,高保真缓冲液25微升,dNTPs 12微升,高保真酶1微升,引物各1微升,双蒸水补齐至50微升。PCR条件为:98℃预变性3min,98℃变性30sec,60℃退火30sec,68℃延伸30sec,40循环。取1微升PCR产物电泳,结果确认为单一条带(123bp),回收PCR产物,用酚-氯仿法纯化后得到转录模板。
C.用T7转录试剂盒体外转录cip2a-gRNA,反应体系为:模板1微克,NTP 4微升,缓冲液2微升,T7酶1微升,DEPC水补至20微升。反应条件为37℃,1h;然后加入1微升DNA酶(TURBO DNase),37℃,15min以去除DNA模板。取1微升转录产物电泳,产物大小约100bp左右,如附图2所示,符合预期,用酚-氯仿法纯化回收得到gRNA。
D.酚-氯仿法纯化方法为:将回收产物用DEPC水补齐至200微升,按体积比1:1加入酚-氯仿,振荡混匀后12,000g离心10min,取上清液于新的去RNA酶1.5毫升离心管中,再加入2.5倍体积的异丙醇,颠倒混匀后置于-80℃,静置30min以上后取出,12,000g离心15min,去掉上清液,留下白色沉淀即为gRNA,加入200微升75%的乙醇清洗gRNA,随后除去乙醇,将离心管开盖置于超净工作台数分钟,晾干gRNA后加入30微升DEPC水溶解,将得到的gRNA溶液保存置-80℃备用。
4.进一步的,制备Cas9 mRNA,具体步骤如下:
A.用限制性内切酶线性化pSP6-spCas9载体,取0.5微升酶切产物电泳,确认线性化完全后回收,并进行纯化处理。
B.用SP6体外转录试剂盒转录线性化载体,转录体系为:10微升2x NTP/CAP,2微升10x缓冲液,2微升SP6转录酶,1微克载体,DEPC水补齐至20微升。反应条件为,37℃,2h,随即加入1微升DNA酶,去除DNA模板。纯化回收得到Cas9 mRNA,取0.5微升产物电泳,1%琼脂糖凝胶,产物大小约2,000bp。
C.Cas9 mRNA添加ployA序列,体系为:回收的mRNA,5微升10mM ATP,5微升10x缓冲液,1微升E.coli Poly(A)聚合酶,DEPC水补至50微升。反应条件为,37℃,1h。纯化回收得到Cas9 mRNA-ployA,取0.5微升产物电泳,1%琼脂糖凝胶,产物大小约2,000bp。
5.进一步的,所述的制备RNA实验中,各部分实验所用耗材和试剂都是去RNA酶的,实验中未明确表明温度的,产物和试剂应保持在4℃以下,避免RNA受热降解。
6.进一步的,所述的制备F0斑马鱼并检测cip2a基因靶点突变效率,通过显微注射和PCR测序来完成,其具体方法如下:
A.预先配置注射体系,包括Cas9 mRNA和cip2a-gRNA,加入1/10体积酚红,作为指示剂,注射到单细胞期胚胎中,注射约200枚胚胎,注射剂量为Cas9 mRNA 300pg,gRNA 50-100pg。
B.取注射后第2天发育正常的胚胎10枚,碱裂解法提取基因组DNA:将胚胎置于PCR管中,加入100微升50mM NaOH溶液,PCR仪加热到95℃,30min裂解胚胎,取出后振荡均匀,加入1/10体积pH8.0的Tris-HCl中和NaOH。
C.用引物P1和P2扩增基因组DNA,将PCR产物通过TA克隆连接至T载体上,测序检测突变类型,结果显示有两种突变类型,分别为缺失7个碱基和4个碱基,如附图1所示。将突变效率较高的F0胚胎饲养起来,用于后续检测筛选可遗传的突变。
7.进一步的,所述的检测F0斑马鱼生殖遗传的方法如下:
A.取性成熟的F0成鱼和野生型成鱼外交,得到F1胚胎,随机挑选5-10个胚胎混合提取基因组DNA。
B.用PCR扩增靶位点片段,PCR产物通过TA克隆测序,确定其突变类型。表明F0斑马鱼cip2a基因突变可以遗传,随后饲养可遗传突变的F1,以备后续筛选。
8.进一步的,所述的确认F1斑马鱼cip2a基因突变类型,方法如下:
A.F1长到1-2月龄,剪取尾鳍,提取基因组DNA。
B.通过PCR分析和TA克隆测序,进一步确认F1斑马鱼cip2a基因突变类型,筛选得到2种突变类型的F1斑马鱼,命名为MT-1和MT-2,相同突变类型的F1可以混合饲养。
9.进一步的,所述的筛选F2斑马鱼cip2a基因纯合突变体,具体方法是:将相同突变的F1成鱼进行自交,得到F2胚胎,饲养至1-2月龄,通过剪尾鳍,提基因组,PCR,测序确认F2斑马鱼纯合突变。得到相同突变的纯合子后,通过自交即可获得大量纯合突变后代,即建立起了可稳定遗传的cip2a基因突变体。
实施例2
本发明一较佳实施例提供一种利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体,其具体特征在于:
1.所述的cip2a基因突变体包含两个品系,具有不同的突变类型;
2.所述的cip2a基因突变体,其突变类型分别为缺失7个碱基和4个碱基;
3.所述的cip2a基因突变体,突变缺失碱基位于靶位点附近;
4.所述的cip2a基因突变体,其突变序列如附图1所示;
5.所述的cip2a基因突变体,其蛋白翻译提前终止,野生型cip2a蛋白有896个氨基酸,而突变体中,缺失7个碱基和4个碱基分别对应了426个氨基酸和258个氨基酸。
6.所述的cip2a基因突变体,为进一步研究cip2a的功能提供了材料基础,有助于在癌症治疗的预后和功能相关性等方面发挥作用。
以上所述仅是本发明的优选实施方法,并不用于限制本发明,应当指出,对于本发明领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变形,这些改进和变形也应视为本发明的保护范围。
本发明由国家自然科学基金(青年科学基金项目——81502500)、江苏省自然科学基金(青年科学基金项目——BK20150293)及苏州市民生科技(医疗卫生应用基础研究项目——SYS2018074)提供资助。
Claims (9)
1.一种利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述突变体构建包括如下步骤:
(1)在cip2a基因上选择Cas9靶位点;
(2)分析确认cip2a-Cas9靶位点;
(3)制备Cas9mRNA和cip2a-gRNA;
(4)制备F0斑马鱼并检测cip2a基因靶点突变效率;
(5)检测F0斑马鱼的生殖遗传;
(6)确认F1斑马鱼cip2a基因突变类型;
(7)筛选F2斑马鱼cip2a基因纯合突变体。
2.根据权利要求1所述的利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的cip2a基因Cas9靶位点设计方法如下:
(1)从Ensemble网站上获取cip2a的蛋白编码序列(CDS);
(2)运用ZiFiT Targeter Version 4.2网站设计靶位点,打开网站,输入cip2a蛋白编码序列;
(3)设定靶位点长度为20个碱基,靶点3’端的3个碱基构成PAM区,序列为NGG(N为任意碱基),输出靶位点序列;
(4)cip2a基因的Cas9靶位点序列为:
5’-CCAGTCACGCACTGACCGGGACC-3’,为反义链靶点,位于第2个外显子。
3.根据权利要求1所述的利用CRISPR-Cas9构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的确认cip2a-Cas9靶位点的方法如下:
(1)在Ensemble网站上比对靶位点序列,比对结果显示靶点是cip2a基因的单一位点;
(2)在靶位点上下游设计引物
5’端引物为,5’-GAGTGCTGTTCTCGGGTCAG-3’,命名为P1,
3’端引物为,5’-ATACCAAATTGTGCCAGCAG-3’,命名为P2,
产物大小为123个碱基对,从野生型斑马鱼基因组中PCR扩增这段序列,其中应包含靶点序列,扩增产物电泳大小符合预期;
(3)将PCR产物进行测序,测序结果和预测靶点序列一致。
4.根据权利要求1所述的利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的制备cip2a-gRNA和Cas9mRNA的方法如下:
(1)制备cip2a-gRNA,具体步骤如下:
A.根据靶位点设计gRNA转录模板的上游引物,命名为P3,序列为,5’-GATCACTAATACGACTCACTATAGGTCCCGGTCAGTGCGTGACGTTTTAGAGCTAGAAAT-3’,下游引物使用pT7-gRNA质粒上的通用引物,命名为P4;
B.用P3和P4引物对,以体外转录载体pT7-gRNA质粒为模板,使用高保真酶PCR扩增得到cip2a-gRNA体外转录模板,PCR体系为:模板1微升,高保真缓冲液25微升,dNTPs12微升,高保真酶1微升,引物各1微升,双蒸水补齐至50微升;PCR条件为:98℃预变性3min,98℃变性30sec,60℃退火30sec,68℃延伸30sec,40循环;取1微升PCR产物电泳,结果确认为单一条带(123bp),回收PCR产物,用酚-氯仿法纯化后得到转录模板;
C.用T7转录试剂盒体外转录cip2a-gRNA,反应体系为:模板1微克,NTP 4微升,缓冲液2微升,T7酶1微升,DEPC水补至20微升;反应条件为37℃,1h;然后加入1微升DNA酶(TURBODNase),37℃,15min以去除DNA模板;取1微升转录产物电泳,产物大小约100bp左右,符合预期,用酚-氯仿法纯化回收得到gRNA;
D.酚-氯仿法纯化方法为:将回收产物用DEPC水补齐至200微升,按体积比1:1加入酚-氯仿,振荡混匀后12,000g离心10min,取上清液于新的去RNA酶1.5毫升离心管中,再加入2.5倍体积的异丙醇,颠倒混匀后置于-80℃,静置30min以上后取出,12,000g离心15min,去掉上清液,留下白色沉淀即为gRNA,加入200微升75%的乙醇清洗gRNA,随后除去乙醇,将离心管开盖置于超净工作台数分钟,晾干gRNA后加入30微升DEPC水溶解,将得到的gRNA溶液保存置-80℃备用;
(2)制备Cas9mRNA,具体步骤如下:
A.用限制性内切酶线性化pSP6-spCas9载体,取0.5微升酶切产物电泳,确认线性化完全后回收,并进行纯化处理;
B.用SP6体外转录试剂盒转录线性化载体,转录体系为:10微升2xNTP/CAP,2微升10x缓冲液,2微升SP6转录酶,1微克载体,DEPC水补齐至20微升;反应条件为,37℃,2h,随即加入1微升DNA酶,去除DNA模板;纯化回收得到Cas9mRNA,取0.5微升产物电泳,1%琼脂糖凝胶,产物大小约2,000bp;
C.Cas9mRNA添加ployA序列,体系为:回收的mRNA,5微升10mMATP,5微升10x缓冲液,1微升E.coli Poly(A)聚合酶,DEPC水补至50微升;反应条件为,37℃,1h;纯化回收得到Cas9mRNA-ployA,取0.5微升产物电泳,1%琼脂糖凝胶,产物大小约2,000bp;
(3)各部分实验所用耗材和试剂都是去RNA酶的,实验中未明确表明温度的,产物和试剂应保持在4℃以下,避免RNA受热降解。
5.根据权利要求1所述的利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的制备F0斑马鱼并检测cip2a基因靶点突变效率,通过显微注射和PCR测序来完成,其具体方法如下:
(1)预先配置注射体系,包括Cas9mRNA和cip2a-gRNA,加入1/10体积酚红,作为指示剂,注射到单细胞期胚胎中,注射约200枚胚胎,注射剂量为Cas9mRNA 300pg,gRNA 50-100pg;
(2)取注射后第2天发育正常的胚胎10枚,碱裂解法提取基因组DNA:将胚胎置于PCR管中,加入100微升50mM NaOH溶液,PCR仪加热到95℃,30min裂解胚胎,取出后振荡均匀,加入1/10体积pH8.0的Tris-HCl中和NaOH;
(3)用引物P1和P2扩增基因组DNA,将PCR产物通过TA克隆连接至T载体上,测序检测突变类型;将突变效率较高的F0胚胎饲养起来,用于后续检测筛选可遗传的突变。
6.根据权利要求1所述的利用CRISPR-Cas9技术构建的斑马鱼cip2a基因突变体的方法,其特征在于,所述的检测F0斑马鱼生殖遗传的方法如下:
(1)取性成熟的F0成鱼和野生型成鱼外交,得到F1胚胎,随机挑选5-10个胚胎混合提取基因组DNA;
(2)用PCR扩增靶位点片段,PCR产物通过TA克隆测序,确定其突变类型;表明F0斑马鱼cip2a基因突变可以遗传,随后饲养可遗传突变的F1,以备后续筛选。
7.根据权利要求1所述的利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的确认F1斑马鱼cip2a基因突变类型,方法如下:
(1)F1长到1-2月龄,剪取尾鳍,提取基因组DNA;
(2)通过PCR分析和TA克隆测序,进一步确认F1斑马鱼cip2a基因突变类型,筛选得到2种突变类型的F1斑马鱼,命名为Allele-1和Alele-2,相同突变类型的F1可以混合饲养。
8.根据权利要求1所述的利用CRISPR-Cas9技术构建斑马鱼cip2a基因突变体的方法,其特征在于,所述的筛选F2斑马鱼cip2a基因纯合突变体,具体方法是,将相同突变的F1成鱼进行自交,得到F2胚胎,饲养至1-2月龄,通过剪尾鳍,提基因组,PCR,测序确认F2斑马鱼纯合突变;得到相同突变的纯合子后,通过自交即可获得大量纯合突变后代,即建立起了可稳定遗传的cip2a基因突变体。
9.一种斑马鱼cip2a基因突变体,其特征在于,所述斑马鱼cip2a基因突变体是使用权利要求1-8中任意一项的方法构建的。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811032925.9A CN109082426A (zh) | 2018-09-05 | 2018-09-05 | 利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811032925.9A CN109082426A (zh) | 2018-09-05 | 2018-09-05 | 利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109082426A true CN109082426A (zh) | 2018-12-25 |
Family
ID=64840732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811032925.9A Pending CN109082426A (zh) | 2018-09-05 | 2018-09-05 | 利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109082426A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110402893A (zh) * | 2019-06-20 | 2019-11-05 | 中山大学 | 一种Nrf2基因缺失斑马鱼突变体的制备及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105594664A (zh) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | 一种stat1a基因缺失型斑马鱼 |
CN106191112A (zh) * | 2016-07-27 | 2016-12-07 | 湖南师范大学 | 一种基因敲除选育wnt16基因缺失型斑马鱼的方法 |
CN106191110A (zh) * | 2016-07-15 | 2016-12-07 | 湖南师范大学 | 一种wnt16基因缺失型斑马鱼 |
-
2018
- 2018-09-05 CN CN201811032925.9A patent/CN109082426A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105594664A (zh) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | 一种stat1a基因缺失型斑马鱼 |
CN106191110A (zh) * | 2016-07-15 | 2016-12-07 | 湖南师范大学 | 一种wnt16基因缺失型斑马鱼 |
CN106191112A (zh) * | 2016-07-27 | 2016-12-07 | 湖南师范大学 | 一种基因敲除选育wnt16基因缺失型斑马鱼的方法 |
Non-Patent Citations (2)
Title |
---|
NCBI: "Danio rerio cell proliferation regulating inhibitor of protein phosphatase 2A (cip2a), mRNA", 《NCBI》 * |
SHINSUKE S等: "Characterization of the RNA-binding protein Musashi1 in zebrafish", 《BRAIN RESEARCH》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110402893A (zh) * | 2019-06-20 | 2019-11-05 | 中山大学 | 一种Nrf2基因缺失斑马鱼突变体的制备及其应用 |
CN110402893B (zh) * | 2019-06-20 | 2021-01-22 | 中山大学 | 一种Nrf2基因缺失斑马鱼突变体的制备及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bai et al. | CRISPR/Cas9-mediated precise genome modification by a long ssDNA template in zebrafish | |
Vesely et al. | Adenosine deaminases that act on RNA induce reproducible changes in abundance and sequence of embryonic miRNAs | |
CN107099533A (zh) | 一种特异靶向猪IGFBP3基因的sgRNA导向序列及应用 | |
Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
CN106834347A (zh) | 一种山羊cdk2基因敲除载体及其构建方法 | |
AU2017101108A4 (en) | Construction method of animal model of mucopolysaccharidosis type II and use thereof | |
Su et al. | The integrative analysis of microRNA and mRNA expression in mouse uterus under delayed implantation and activation | |
US20220136041A1 (en) | Off-Target Single Nucleotide Variants Caused by Single-Base Editing and High-Specificity Off-Target-Free Single-Base Gene Editing Tool | |
WO2022156378A1 (zh) | 基因转录框架、载体系统、基因组序列编辑方法及应用 | |
US20230416747A1 (en) | Safe harbor loci | |
CN108753834B (zh) | ddx27基因缺失斑马鱼突变体的制备方法 | |
WO2017215517A1 (zh) | 测序文库构建中5'和3'接头连接副产物的去除方法 | |
CN110066805A (zh) | 基因敲除选育adgrf3b基因缺失型斑马鱼的方法 | |
EP4026910A1 (en) | Method for evaluating gene editing therapy based on off-target assessment | |
CN109082426A (zh) | 利用CRISPR-Cas9构建的斑马鱼cip2a基因突变体及其构建方法 | |
CN106544360B (zh) | 一种终止lncRNA双等位基因转录的方法 | |
Morillon | Long Non-coding RNA: The Dark Side of the Genome | |
CN109082427A (zh) | 利用CRISPR-Cas9构建的斑马鱼msi1基因突变体及其构建方法 | |
CN109136351A (zh) | 一种通过扩增子高通量测序技术检测sgRNA活性和特异性的方法 | |
AU2019247490A1 (en) | Compositions and methods for somatic cell reprogramming and modulating imprinting | |
CN111088253A (zh) | 针对hbb-28地中海贫血基因的crispr单碱基供体修复体系 | |
CN115261360A (zh) | 一种gata6基因敲除斑马鱼模型的构建方法 | |
CN114480497A (zh) | 一种ep400基因敲除斑马鱼心力衰竭模型的构建及其应用的方法 | |
CN113897361A (zh) | 一种eef1b2基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
Watanabe et al. | Lipofection with Lipofectamine™ 2000 in a heparin‐free growth medium results in high transfection efficiency in chicken primordial germ cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |